In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to Legend Biotech (LEGN – Research Report).

Legend Biotech Corporation (NASDAQ:LEGN) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, ...

Legend Biotech Corporation ( (LEGN) ) has released its Q3 earnings. Here is a breakdown of the information Legend Biotech Corporation presented ...

Shares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week.

CARVYKTI demonstrated a 45% reduction in the risk of death compared to standard therapies in multiple myeloma patients.

Ladies and gentlemen, thank you for standing by. Welcome to Legend Biotech reports third quarter 2024 financial results. (Operator Instructions) Please be advised that today's conference is being ...

On Friday, Legend Biotech Corp (LEGN) stock saw a decline, ending the day at $40.03 which represents a decrease of $-0.92 or -2.25% from the prior close of $40.95. The stock opened at $40.61 and ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

Arcellx has shared several data cuts on anito-cel, a CAR-T being developed with Gilead’s Kite Pharma to treat relapsed or ...

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

Shares of Legend Biotech Corporation Sponsored ADR (LEGN) have been struggling lately and have lost 9.8% over the past week. However, a hammer chart pattern was formed in its last trading session ...